Today the dispute settlement panel formed under the United States-Mexico-Canada Agreement (USMCA) issued a final ruling related to Mexico's restrictions on the importation of genetically modified (GM) ...

Before we head out for the holidays, we're back with some breaking news about a few of BIO's legislative priorities. Happy Holidays and Happy New Year! We'll see you in 2025 (unless there's major ...

John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), today released the following statement ahead of an expected vote in the U.S. House of Representatives on a ...

Today, the Biotechnology Innovation Organization (BIO) named Sarah Alspach as its new executive vice president and chief communications officer. Alspach, a communications veteran, will join BIO’s ...

A busy Monday brings louder calls for PBM reform, plus a report on U.S. biotech economic output and jobs, news on avian flu and plant biotech regulations, and more. (834 words, 4 minutes, 10 seconds) ...

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic ...

Hope you enjoyed the holiday weekend. We’re back with BIO’s Bio.News series on the problems with PBMs, plus a recap of BIO’s IP Counsels Committee Conference and more news you need to know. (573 words ...

Before you begin your Thanksgiving prep, we recap last week's Clinical Trial Diversity Summit, how the "faceless middleman" is raising your healthcare costs, and promising news from USDA. (890 words, ...

Prior to the case study exercise, Silas Buchanan Founding CEO of the Institute for eHealth Equity will provide a framework to use for underserved-community outreach and how to avoid failure points. He ...

Barbara Fiacco is a Partner, co-chair of the Intellectual Property Department and co-chair of the Patent, Trade Secrets, and Related Rights Litigation Practice at Foley Hoag LLP. In her practice, ...

Javeed Froozan’s corporate development experience spans over 25 years in early stage, growth, and large biopharma and health tech firms. This includes acquiring companies, products and technologies in ...

Scott Carmer is the former CEO at NexImmune – a Johns Hopkins incubated spin-out which was based on innovative science developed in the lab of co-founder, Jonathan Schneck. During an eight-year career ...